Clinical Trial Update: Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model [Phase 2]

View source ↗

Summary

Phase 2 trial is recruiting to evaluate an anti-CD25 recombinant human monoclonal antibody for prevention of acute graft-versus-host disease in high-risk adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Anti-CD25 rhMAb (anti-CD25 recombinant human monoclonal antibody)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Graft-versus-Host Disease | Phase 2 | Status: RECRUITING